[1]
|
Bennett, P.H. and Knowler, W.C. (2010) Definition, diagnosis, and classification of diabetes mellitus and glucose homeostasis. In: Kahn, C.R., King, G.L., Moses, A.C., Weir, G.C., Jacobson, A.M. and Smith, R.J., Eds., Joslin’s Diabetes Mellitus, 14th Edition, Walter Kluwer Pvt. Ltd., New Delhi, 331-339.
|
[2]
|
Gavin, J.R., III, Albert, K.G.M.M., Davidson, M.B. et al. (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 20, 1183-1197.
|
[3]
|
Edelstein, S.L., Knowler, W.C., Bain, R.P., et al. (1997) Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies. Diabetes, 46, 701-710. doi:10.2337/diabetes.46.4.701
|
[4]
|
The DECODE Study Group, European Diabetes Epidemiological Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. (1999) Glucose tolerance and mortality: Comparison of WHO and American Diabetes association diagnostic criteria. Lancet, 354, 617-621. doi:10.1016/S0140-6736(98)12131-1
|
[5]
|
Buchanon, T.A., Xiang, A.H., Peters, R.K., et al. (2001) Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping trogitazone. Diabetes, 50, 327.
|
[6]
|
Isommaa, B., Almgren, P., Hericson, M., et al. (1999) Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care, 22, 137-1353. doi:10.2337/diacare.22.8.1347
|
[7]
|
Knowler, W.C., Barret-Connor, E., Fowler, S.E., et al., Diabtes Prevention Program Group (2002) Reduction in the incidence of type 2 diabetes with life style intervention or metformin. The New England Journal of Medicine, 346, 393-403.
|
[8]
|
The Diabetes Prevention Progression Research Group (2002) Reduction in the incidence of type 2 diabetes with life style intervention of metformin. The New England Journal of Medicine, 346, 393-403.
doi:10.1056/NEJMoa012512
|
[9]
|
Groop, L. (2000) Genetics of the metabolic syndrome. British Journal of Nutrition, 83, S39-S48.
|
[10]
|
Olefsky, J.M., Revers, R.R., Prince, M., et al. (1985) Insulin resistance in non-insulin dependent (type II) and insulin dependent (type I) diabetes mellitus. Advances in Experimental Medicine and Biology, 189, 176-205.
|
[11]
|
Ratzmann, K.P., Ruhnke, R. and Kohnert, K.D. (1983) Effect of pharmacological suppression of insulin secretion on tissue sensitivity to insulin in subjects with moderate obesity. International Journal of Obesity, 7, 453-458.
|
[12]
|
Buse, J.B., Polonsky, K.S. and Burant, C.F. (2008) Type 2 diabetes mellitus. In: Kronenberg, H.M., Melmed, S., Polanski, K.S. and Larsen, P.R., Eds., Williams Textbook of ENDOCRINOLOGY, 11th Edition, Volume 1, Elsevier Inc., Saunders, 1330-1389.
|
[13]
|
Long, Y.C. and Zierath, J.R. (2006) AMP—Activated protein kinase signaling in metabolic regulation. Journal of Clinical Investigation, 116, 1776-1783.
doi:10.1172/JCI29044
|
[14]
|
Powers, A.C. (2011) Diabetes Mellitus. In: Longo, D.N., Kasper, D.L., Jameson, J.L., Fauci, A.S., Hauser, S.L. and Loscalzo, J., Eds., Harrison’s Principles of Internal Medicine, 18th Edition, Volume 2, McGraw-Hill Companies, Inc., New York, 2968-3009
|
[15]
|
Powers, A.C. and D’Alessio, D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglicemia. In: Brunton, L.L., Chabner, B.A. and Knollmann, B.C., Eds., Goodman & Gillman’s the Pharmacological Basis of Therapeutics, 12th Edition, McGraw-Hill Companies, Inc., New York, 1237-1273.
|
[16]
|
Musi, N., Hirshman, M.F., Nygren, J. et al. (2002) Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 51, 2074-2081. doi:10.2337/diabetes.51.7.2074
|